Basic Information

Gene symbol CD19 Synonyms B4, CVID3 Type of gene protein-coding
Description CD19 molecule

GTO ID GTC0605
Trial ID ChiCTR1900024456
Disease Acute Lymphoblastic Leukemia
Altered gene CD19
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD19 CAR-T cells
PhaseEarly_Phase1
Recruitment statusRecruiting
TitlePhase I study for autologous anti-CD19 (human derived) chimeric antigen receptor T cells treating refractory or relapsed acute lymphoblastic leukemia
Year2019
CountryChina
Company sponsorBeijing Boren Hospital

Clinical Result

Cohort 1
Administration route None
Donor type Autologous
Pts 19
Age Child, Adult, Older_Adult
Outcome 68%(CR). Among 13 remission patients, 11 underwent allogeneic hematopoietic cell transplantation (allo-HCT) (3 were second HCT) and 10 remained in CR; the event-free survival rates at 12–18 months were 91% in 11 patients received following allo-HCT and 69% in all CR patients.
Adverse reactions 2/19(Grade ≥3 CRS)
References PMID: 35410148

Relationship Graph

Overview of Knowledge Graph